Hello, I’m Gherardo Baudo, a postdoctoral fellow with a Ph.D. in Nanomedicine. I specialize in drug delivery, particularly focusing on biomimetic lipid nanoparticles that encapsulate mRNA and drugs. My research spans diverse medical realms, including osteosarcoma, traumatic brain injury, and neurodegenerative diseases. Recognized as an expert in mitochondria transplantation, I employ this innovative strategy to address various cardiovascular conditions such as pulmonary arterial hypertension (PAH), atherosclerosis, and idiopathic pulmonary fibrosis (IPF). Currently, my research is dedicated to advancing our understanding of Alzheimer’s disease and exploring novel approaches for its treatment. With a comprehensive background in nanomedicine and a proven track record in translational research, I am committed to making significant contributions to the field of medical science.

University of Florence

Mechanical Engineering BE '17, University of Florence

Polytechnic Institute of Turin

Biomedical Engineering MS '20, Polytechnic Institute of Turin

PhD obtained from University Chinese Academy of Science November 2023

Pulmonary And Respiratory Medicine

Biomaterials

Molecular Biology

Oncology

Surgery

Developmental Neuroscience

Immunology

Biomedical Engineering

Physiology

Clinical Psychology

Pathology And Forensic Medicine

Urology

Cellular And Molecular Neuroscience

Ecology

Psychiatry And Mental Health

Public Health, Environmental And Occupational Health

Epidemiology

Periodontics

Biophysics

Endocrinology, Diabetes And Metabolism

Infectious Diseases

Pharmacology

Ph.D in Material Sciences & Nanomedicine with a MS in Medical Biotechnology & Nanotechnology, achieved with highest honors.  My research investigates the preclinical application of Lipid Nanoparticles for delivery of RNA therapeutics in different diseases stemming from mitochondrial dysfunctions.

Experimental Methods

Matteo Massaro's Org

Detailed protocol for MTT Cell Viability and Proliferation Assay

The MTT Cell Viability and Proliferation Assay is employed to evaluate cellular metabolic activity as an indicator of cell viability, proliferation, and cytotoxicity. This colorimetric method relies on the conversion of a yellow tetrazolium salt (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide or MTT) to purple formazan crystals by metabolically active cells. These cells possess NAD(P)H-dependent oxidoreductase enzymes, which facilitate the reduction of MTT to formazan. Following this reaction, insoluble formazan crystals are dissolved using a solubilization solution, and the resulting colored solution is quantified by measuring absorbance at 500-600 nanometers using a multi-well spectrophotometer. A darker solution indicates a higher number of viable, metabolically active cells.This protocol can be utilized for the following assessments:Quantification of cell growthMeasurement of cytotoxicity (e.g., following anti-cancer drug treatments)Study of cell activationMoreover, since the MTT assay relies on the reduction of MTT to formazan crystals by metabolically active cells involving NAD(P)H-dependent oxidoreductase enzymes, which are present in the mitochondria, the protocol can also be used to assess mitochondrial functions.Cell Viability and Proliferation Assay3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT).Cell culture medium.Phosphate-buffered saline (PBS).Dimethyl sulfoxide (DMSO).Plate reader.Protocol: 1. Cell Seeding:Seed cells in a 96-well microplate with a transparent bottom. Ensure cells are evenly distributed across each well. It's recommended to avoid to seed the cells in the perimeters wells due to the “edge effect”; in fact the perimeter wells are more exposed to the environment and tend to have different evaporation rates compared to the inner wells2. Treatment Application:Prepare the MTT stock solution at a concentration of 0.5 mg/ml in PBS. Store protected from light until use.After the treatment period, carefully add 10 μl of the MTT solution to each well, ensuring not to dislodge the cells.3. Incubation for Formazan Formation:Place the microplate in a humidified incubator set at 37 °C with 5% CO₂ for 4 h. This allows for the reduction of MTT by metabolically active cells to form purple formazan crystals, visible under a microscope.4. Removal of Medium and MTT Solution:After incubation, carefully remove the cell medium and MTT solution from each well using a pipette, taking care not to disturb the formazan crystals at the bottom of the wells.5. Washing:Gently wash each well with PBS to remove any remaining medium and unreacted MTT, ensuring complete removal of PBS in subsequent steps.6. Dissolving Formazan Crystals:Add 100 μl of DMSO to each well to dissolve the formazan crystals. Cover the microplate with aluminum foil to protect from light.7. Shaking:Place the covered plate on an orbital shaker and shake gently at room temperature for 30 min to ensure complete solubilization of the formazan crystals. 8. Measurement:Measure the absorbance of each well using a microplate reader set at 590 nm. Ensure to complete the readings within 1 hour of solubilization to avoid precipitation. Should you have any doubt, please tag me in the comments.

Detailed protocol for MTT Cell Viability and Proliferation Assay

Scan to connect with one of our mobile apps

Coinbase Wallet app

Coinbase app

Or try the Coinbase Wallet browser extension